Advertisement
ABT vs CDNA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABT is a Buy and CDNA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABT’s FA Score shows that 2 FA rating(s) are green whileCDNA’s FA Score has 0 green FA rating(s).
- ABT’s FA Score: 2 green, 3 red.
- CDNA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABT’s TA Score shows that 4 TA indicator(s) are bullish while CDNA’s TA Score has 5 bullish TA indicator(s).
- ABT’s TA Score: 4 bullish, 6 bearish.
- CDNA’s TA Score: 5 bullish, 5 bearish.
Price Growth
ABT (@Medical Specialties) experienced а +2.32% price change this week, while CDNA (@Medical Specialties) price change was +7.34% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +3.05%. For the same industry, the average monthly price growth was +5.16%, and the average quarterly price growth was -1.87%.
Reported Earning Dates
ABT is expected to report earnings on Oct 15, 2025.
CDNA is expected to report earnings on Aug 06, 2025.
Industries' Descriptions
@Medical Specialties (+3.05% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ABT | CDNA | ABT / CDNA | |
| Capitalization | 194B | 548M | 35,401% |
| EBITDA | 10.5B | -84.92M | -12,365% |
| Gain YTD | 13.489 | -40.262 | -34% |
| P/E Ratio | 34.38 | N/A | - |
| Revenue | 40.1B | 280M | 14,321% |
| Total Cash | 7.28B | 235M | 3,097% |
| Total Debt | 15.6B | 34.2M | 45,614% |
ABT | CDNA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 42 | 100 | |
SMR RATING 1..100 | 32 | 46 | |
PRICE GROWTH RATING 1..100 | 60 | 94 | |
P/E GROWTH RATING 1..100 | 96 | 94 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABT's Valuation (11) in the Medical Specialties industry is significantly better than the same rating for CDNA (96). This means that ABT’s stock grew significantly faster than CDNA’s over the last 12 months.
ABT's Profit vs Risk Rating (42) in the Medical Specialties industry is somewhat better than the same rating for CDNA (100). This means that ABT’s stock grew somewhat faster than CDNA’s over the last 12 months.
ABT's SMR Rating (32) in the Medical Specialties industry is in the same range as CDNA (46). This means that ABT’s stock grew similarly to CDNA’s over the last 12 months.
ABT's Price Growth Rating (60) in the Medical Specialties industry is somewhat better than the same rating for CDNA (94). This means that ABT’s stock grew somewhat faster than CDNA’s over the last 12 months.
CDNA's P/E Growth Rating (94) in the Medical Specialties industry is in the same range as ABT (96). This means that CDNA’s stock grew similarly to ABT’s over the last 12 months.
| ABT | CDNA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 62% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 58% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 48% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 52% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 57% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 50% | 2 days ago 88% |
| Advances ODDS (%) | 4 days ago 58% | 4 days ago 83% |
| Declines ODDS (%) | 18 days ago 49% | 2 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 56% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 51% | 2 days ago 87% |
Advertisement
ABT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABT has been loosely correlated with SYK. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ABT jumps, then SYK could also see price increases.
CDNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with NTRA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then NTRA could also see price increases.
| Ticker / NAME | Correlation To CDNA | 1D Price Change % | ||
|---|---|---|---|---|
| CDNA | 100% | -0.39% | ||
| NTRA - CDNA | 42% Loosely correlated | -1.53% | ||
| VCYT - CDNA | 41% Loosely correlated | +7.04% | ||
| BLFS - CDNA | 39% Loosely correlated | +1.44% | ||
| LMAT - CDNA | 35% Loosely correlated | +2.06% | ||
| ABT - CDNA | 35% Loosely correlated | +0.72% | ||
More | ||||